Xenon Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Xenon Pharmaceuticals Inc cash flow-to-debt ratio. Xenon Pharmaceuticals Inc (XENE) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of $-81.48 Million could theoretically repay 0% of its total liabilities ($399.91 Million) in one year. Check Xenon Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Xenon Pharmaceuticals Inc (2012–2025)
Cash flow-to-debt ratio of Xenon Pharmaceuticals Inc from 2012 to 2025. Historical debt coverage capacity for Xenon Pharmaceuticals Inc across 14 annual periods. Check XENE capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Xenon Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2012–2025)
Xenon Pharmaceuticals Inc cash flow-to-debt ratio by year from 2012 to 2025. Year-by-year debt coverage analysis for Xenon Pharmaceuticals Inc. For the full cash flow conversion analysis, see Xenon Pharmaceuticals Inc (XENE) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-279.12 Million | $399.91 Million | ▲ +83.4% |
| 2024 | -4.20x | $-181.39 Million | $43.24 Million | ▼ -6.5% |
| 2023 | -3.94x | $-145.33 Million | $36.88 Million | ▼ -30.7% |
| 2022 | -3.01x | $-98.43 Million | $32.65 Million | ▲ +4.7% |
| 2021 | -3.16x | $-69.50 Million | $21.97 Million | ▼ -17.2% |
| 2020 | -2.70x | $-48.12 Million | $17.83 Million | ▼ -3146.6% |
| 2019 | -0.08x | $-4.63 Million | $55.72 Million | ▲ +95.4% |
| 2018 | -1.81x | $-34.72 Million | $19.13 Million | ▲ +35.6% |
| 2017 | -2.82x | $-28.73 Million | $10.19 Million | ▲ +48.3% |
| 2016 | -5.46x | $-19.57 Million | $3.59 Million | ▲ +12.1% |
| 2015 | -6.21x | $-18.10 Million | $2.92 Million | ▼ -34277.6% |
| 2014 | 0.02x | $266.00K | $14.64 Million | ▲ +116.6% |
| 2013 | -0.11x | $-3.32 Million | $30.37 Million | ▼ -112.2% |
| 2012 | 0.90x | $45.57 Million | $50.68 Million | — |